Tri Locum Partners
Latest statistics and disclosures from Tri Locum Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are JNJ, ISRG, TMO, ASND, VRTX, and represent 49.57% of Tri Locum Partners's stock portfolio.
- Added to shares of these 9 stocks: ISRG (+$71M), TMO (+$65M), VRTX (+$58M), JAZZ (+$30M), TARS (+$18M), DXCM (+$17M), MDGL (+$9.0M), DFTX (+$7.0M), NUVL.
- Started 6 new stock positions in VRTX, JAZZ, TMO, TARS, DFTX, ISRG.
- Reduced shares in these 10 stocks: DHR (-$79M), BSX (-$50M), JNJ (-$46M), IONS (-$44M), VERA (-$41M), DNTH (-$40M), UTHR (-$30M), AXSM (-$24M), TEVA (-$13M), ARGX.
- Sold out of its positions in BSX, DHR, IONS, VERA.
- Tri Locum Partners was a net seller of stock by $-99M.
- Tri Locum Partners has $713M in assets under management (AUM), dropping by -7.48%.
- Central Index Key (CIK): 0001826434
Tip: Access up to 7 years of quarterly data
Positions held by Tri Locum Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tri Locum Partners
Tri Locum Partners holds 17 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | 14.2 | $101M | -31% | 415k | 244.44 |
|
| Intuitive Surgical Com New (ISRG) | 9.9 | $71M | NEW | 153k | 460.99 |
|
| Thermo Fisher Scientific (TMO) | 9.1 | $65M | NEW | 132k | 491.53 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 8.2 | $58M | -3% | 255k | 228.73 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 8.1 | $58M | NEW | 129k | 446.54 |
|
| Eli Lilly & Co. (LLY) | 8.0 | $57M | -2% | 62k | 919.77 |
|
| Madrigal Pharmaceuticals (MDGL) | 7.6 | $54M | +20% | 103k | 523.47 |
|
| Dex (DXCM) | 6.2 | $44M | +65% | 698k | 62.80 |
|
| United Therapeutics Corporation (UTHR) | 5.9 | $42M | -41% | 70k | 592.98 |
|
| Nuvalent Inc-a (NUVL) | 4.4 | $32M | 309k | 102.45 |
|
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 4.3 | $31M | -28% | 1.0M | 30.12 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 4.2 | $30M | NEW | 159k | 189.05 |
|
| Argenx Se Sponsored Adr (ARGX) | 3.2 | $23M | -15% | 32k | 730.25 |
|
| Tarsus Pharmaceuticals (TARS) | 2.5 | $18M | NEW | 253k | 70.15 |
|
| Dianthus Therapeutics (DNTH) | 1.7 | $12M | -76% | 146k | 83.92 |
|
| Axsome Therapeutics (AXSM) | 1.5 | $11M | -69% | 62k | 169.02 |
|
| Definium Therapeutics Com Shs (DFTX) | 1.0 | $7.0M | NEW | 370k | 18.90 |
|
Past Filings by Tri Locum Partners
SEC 13F filings are viewable for Tri Locum Partners going back to 2020
- Tri Locum Partners 2026 Q1 filed May 18, 2026
- Tri Locum Partners 2025 Q4 filed Feb. 17, 2026
- Tri Locum Partners 2025 Q3 filed Nov. 14, 2025
- Tri Locum Partners 2025 Q2 filed Aug. 14, 2025
- Tri Locum Partners 2025 Q1 filed May 14, 2025
- Tri Locum Partners 2024 Q4 filed Feb. 14, 2025
- Tri Locum Partners 2024 Q3 filed Nov. 14, 2024
- Tri Locum Partners 2024 Q2 filed Aug. 14, 2024
- Tri Locum Partners 2024 Q1 filed May 15, 2024
- Tri Locum Partners 2023 Q4 filed Feb. 14, 2024
- Tri Locum Partners 2023 Q3 filed Nov. 14, 2023
- Tri Locum Partners 2023 Q2 filed Aug. 14, 2023
- Tri Locum Partners 2023 Q1 filed May 15, 2023
- Tri Locum Partners 2022 Q4 filed Feb. 14, 2023
- Tri Locum Partners 2022 Q3 filed Nov. 14, 2022
- Tri Locum Partners 2022 Q2 filed Aug. 15, 2022